ACCELERATING INNOVATION IN NK CELL THERAPY Logo (WIPO, 23.01.2019)
WIPOSchützen Sie diese Marke vor Nachahmern!
Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.
Die Internationale Marke ACCELERATING INNOVATION IN NK CELL THERAPY wurde als Wortmarke am 23.01.2019 bei der Weltorganisation für geistiges Eigentum angemeldet.
| Markenform | Wortmarke |
| Aktenzeichen | 1478321 |
| Länder | 
|
| Basismarke |
Nr. 88048416,
23. Juli 2018
|
| Anmeldedatum | 23. Januar 2019 |
| Ablaufdatum | 11. Juli 2022 |
Markeninhaber
Paasheuvelweg 25A
1105 BP Amsterdam
NL
1105 BP Amsterdam
NL
Markenvertreter
31 rue de Fleurus
F-75006 Paris
FR
Waren und Dienstleistungen
05
Pharmaceutical preparations for the treatment of immuno
oncological disorders, cancer, diabetes, respiratory, heart,
neurological and auto immune disorders; stem cells for
medical purposes; living cells for medical use; biological
preparations for the treatment of cancer; therapeutics
utilizing NC cells for use in the treatment of cancer,
autoimmune disease and infectious diseases; cell
preparations, cellular vaccines and cellular biologics for
the treatment of cancer and infectious diseases by
autologous cell-based immunotherapy
42
Scientific and technological services, namely, scientific
research, design, analysis and testing in the field of
cancer evolution and new cancer therapies using natural
killer cells; industrial research in the field of new
pharmaceutical products and new cancer therapies; medical
and veterinary research services in the nature of the
manipulation of cells within a laboratory or research
facility to enable natural killer cells to be used for
medical or therapeutic purposes; scientific research in the
development of new cancer therapies; scientific research in
human and animal cell therapy; scientific research into
preparations for manipulating and adapting human and animal
cells; consultancy relating to all the aforesaid services;
conducting research and clinical trials for others relating
to the use and the engineering of natural killer cells and
cancer treatment and therapy; medical and scientific
research in the field of cancer treatment and diagnosis;
data collection for others for research purposes, namely,
the collection, testing and research of patient molecular
and genomic data; collection and preservation of human and
animal DNA for research purposes
44
Medical testing for diagnostic or treatment purposes in the
field of cancer research; medical diagnostic testing,
monitoring and reporting services; medical evaluation of
immuno oncological disorders, cancer, diabetes, respiratory,
heart, neurological and auto immune disorders; medical
monitoring services; medical diagnostic, prognostic and
theranostic screening and testing services; collection and
preservation of DNA for medical purposes; consulting
services in the nature of providing medical information;
consulting services in the field of healthcare and cancer
diagnoses; providing a website featuring health and
healthcare information related to cancer, testing and
screening; genetic testing for medical purposes; providing
information in the field of cancer prevention, screening,
diagnosis and treatment for medical diagnostic and treatment
purposes; providing genetics assessments in the nature of
genetic counseling; genetic testing for medical diagnostic
purposes; genomic testing for medical diagnostic purposes;
Gene analysis and sequencing and DNA analysis and sequencing
for medical diagnostic purposes and veterinary diagnostics
purposes; gene analysis and sequencing and DNA analysis and
sequencing for use in cancer diagnosis and treatment;
providing health and healthcare information related to
cancer research, via a website
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen
Markenhistorie
| Datum | Belegnummer | Bereich | Eintrag |
|---|---|---|---|
| 17. Februar 2023 | 2023/10 Gaz | US | RAW: Total Ceasing Effect |
| 27. Januar 2022 | 2022/5 Gaz | JP | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 20. Februar 2021 | 2021/9 Gaz | AU | Ablehnung |
| 16. Dezember 2020 | 2021/4 Gaz | KR | Ablehnung |
| 10. September 2020 | 2020/37 Gaz | JP | Ablehnung |
| 19. Juni 2020 | 2020/27 Gaz | EM | Ablehnung |
| 25. Mai 2020 | 2020/22 Gaz | KR | Ablehnung |
| 24. Mai 2020 | 2020/22 Gaz | AU | Ablehnung |
| 10. Dezember 2019 | 2019/50 Gaz | GB | Ablehnung |
| 13. November 2019 | 2019/46 Gaz | AU | Ablehnung |
| 16. Oktober 2019 | 2019/43 Gaz | CN | Ablehnung |
| 16. September 2019 | 2019/41 Gaz | EM | Ablehnung |
| 30. Juli 2019 | 2019/31 Gaz | GB | Ablehnung |
| 23. Januar 2019 | 2019/28 Gaz | US | Eintragung |
ID: 141478321